The possibility of 5 Fast Track Vouchers worth AU$750m.
Taureanbull, as I've posted before, the rare pediatric priority review voucher program is due to expire in October 2020. After that date, only drugs already designated as rare paediatric treatments and which receive marketing approval by October 2022 can receive a voucher. Trofinetide in Rett syndrome might scrape through for marketing approval by that date, but any other indications won’t.
Also, ACAD shareholders are already entitled to receive two thirds of any PRV that trofinetide receives under the existing North American licensing deal.
NEU Price at posting:
$2.03 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)